|
Index of reports
> Cases with Infection (257)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Cyclophosphamide where reactions include infection. The selected reports were submitted to the FDA during the sample period of about a year. Reports 1 - 30 of 257 Next >>
Possible Cyclophosphamide side effects in 49 year old male
Reported by a physician from Norway on 2012-08-27
Patient: 49 year old male
Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Septic Shock, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Bleomycin Sulfate
Dosage: 10000 iu, day 8 (2 escalated cycles)
Indication: Hodgkin's Disease
Bleomycin Sulfate
Dosage: 10000 iu, day 8 (4 standard cycles)
Cyclophosphamide
Dosage: 650 mg/m2, day 1 (4 standard cycles)
Cyclophosphamide
Dosage: 1250 mg/m2, day 1 (2 escalated cycles)
Indication: Hodgkin's Disease
Doxorubicin HCL
Dosage: 25 mg/m2, day 1 (4 standard cycles)
Doxorubicin HCL
Dosage: 35 mg/m2, day 1 (2 escalated cycles)
Indication: Hodgkin's Disease
Etoposide
Dosage: 100 mg/m2, day 1-3 (4 standard cycles)
Etoposide
Dosage: 200 mg/m2, day 1-3 (2 escalated cycles)
Indication: Hodgkin's Disease
Prednisolone
Dosage: 40 mg/m2, day 1-14 (4 standard cycles)
Administration route: Oral
Prednisolone
Dosage: 40 mg/m2, day 1-14 (2 escalated cycles)
Administration route: Oral
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: 100 mg/m2, day 1-7 (2 escalated cycles)
Administration route: Oral
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: 100 mg/m2, day 1-7 (4 standard cycles)
Administration route: Oral
Vincristine
Dosage: 1.4 mg/m2, day 8 (2 escalated cycles)
Indication: Hodgkin's Disease
Vincristine
Dosage: 1.4 mg/m2, day 8 (4 standard cycles)
Possible Cyclophosphamide side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-27
Patient:
Reactions: Off Label Use, Gastrointestinal Toxicity, Neutropenia, Infection
Drug(s) suspected as cause:
Carboplatin
Dosage: 6 courses in high risk
Indication: Retinoblastoma
Cyclophosphamide
Indication: Retinoblastoma
Doxorubicin Hydrochloride
Dosage: 4 courses in intermediate risk and 6 courses in high risk
Indication: Retinoblastoma
Etoposide
Indication: Retinoblastoma
Vincristine
Dosage: 4 courses in intermediate risk and 6 courses in high risk
Indication: Retinoblastoma
Other drugs received by patient: Neupogen
Possible Cyclophosphamide side effects in 49 year old male
Reported by a physician from Norway on 2012-08-27
Patient: 49 year old male
Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Pyrexia, Lung Infiltration, Septic Shock, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Bleomycin Sulfate
Dosage: on day 8
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: for escalated cycles on day 1
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: for standard cycles on day 1
Doxorubicin Hydrochloride
Dosage: for escalated cycles on day 1
Indication: Hodgkin's Disease
Doxorubicin Hydrochloride
Dosage: on day 1,for standard cycles
Etoposide
Dosage: for the escalated cycles on day 1 to 3
Etoposide
Dosage: for the escalated cycles on day 1 to 3
Etoposide
Dosage: for the standard cycles, day 1 to 3
Indication: Hodgkin's Disease
Prednisolone
Dosage: on day 1 to 14 every 21 day cycle treatment for 6 cycles
Administration route: Oral
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: day 1 to 7
Administration route: Oral
Indication: Hodgkin's Disease
Vincristine
Dosage: on day 8
Indication: Hodgkin's Disease
Possible Cyclophosphamide side effects in 49 year old male
Reported by a physician from Norway on 2012-08-24
Patient: 49 year old male
Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Pyrexia, Lung Infiltration, Septic Shock, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Bleomycin Sulfate
Dosage: on day 8
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: for escalated cycles on day 1
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: for standard cycles on day 1
Doxorubicin Hydrochloride
Dosage: on day 1,for standard cycles
Doxorubicin Hydrochloride
Dosage: for escalated cycles on day 1
Indication: Hodgkin's Disease
Etoposide
Dosage: for the escalated cycles on day 1 to 3
Etoposide
Dosage: for the escalated cycles on day 1 to 3
Etoposide
Dosage: for the standard cycles, day 1 to 3
Indication: Hodgkin's Disease
Prednisolone
Dosage: on day 1 to 14 every 21 day cycle treatment for 6 cycles
Administration route: Oral
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: day 1 to 7
Administration route: Oral
Indication: Hodgkin's Disease
Vincristine
Dosage: on day 8
Indication: Hodgkin's Disease
Possible Cyclophosphamide side effects in male
Reported by a consumer/non-health professional from United States on 2012-08-23
Patient: male, weighing 79.0 kg (173.8 pounds)
Reactions: Phlebitis, Hydronephrosis, Adenovirus Infection, Cystitis Haemorrhagic, Human Polyomavirus Infection, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Campath
Dosage: 30 mg/m2, on first 3 days of each cycle (total 6 cycles)
Indication: Chronic Lymphocytic Leukaemia
Start date: 2008-07-15
End date: 2008-12-03
Cyclophosphamide
Dosage: 500 mg/m2, on first 3 days of each cycle (total 6 cycles)
Administration route: Oral
Indication: Chronic Lymphocytic Leukaemia
Start date: 2008-07-15
End date: 2008-12-03
Fludara
Dosage: 80 mg/m2, on first 3 days of each cycle (total 6 cycles)
Administration route: Oral
Indication: Chronic Lymphocytic Leukaemia
Start date: 2008-07-15
End date: 2008-12-03
Other drugs received by patient: Folic Acid; Bactrim; Vfend; Valganciclovir
Possible Cyclophosphamide side effects in male
Reported by a physician from United States on 2012-08-22
Patient: male
Reactions: Rectal Haemorrhage, Constipation, Cardiac Disorder, Hospitalisation, Granulocytopenia, Inappropriate Antidiuretic Hormone Secretion, Thrombocytopenia, Cardiac Failure Congestive, Pneumonia, Anaemia, Pancytopenia, Atrial Fibrillation, Febrile Neutropenia, Syncope, Embolism, Sepsis, Dehydration, Asthenia, Mantle Cell Lymphoma Recurrent, Leukopenia, Deep Vein Thrombosis, Infection
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1
Indication: Mantle Cell Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Indication: Mantle Cell Lymphoma
Leukine
Dosage: on day 9-15; 250 mcg/m2/day
Indication: Mantle Cell Lymphoma
Leukine
Dosage: on day 9-15; 250 mcg/m2/day
Indication: Diffuse Large B-Cell Lymphoma
Prednisone TAB
Dosage: on days 1-5
Indication: Mantle Cell Lymphoma
Prednisone TAB
Dosage: on days 1-5
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: on day 15; as infusion
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: on day 15; as infusion
Indication: Mantle Cell Lymphoma
Vincristine
Dosage: on day 1 (maximum dose: 2mg)
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Dosage: on day 1 (maximum dose: 2mg)
Indication: Mantle Cell Lymphoma
Possible Cyclophosphamide side effects in 56 year old female
Reported by a physician from United States on 2012-08-22
Patient: 56 year old female, weighing 91.2 kg (200.6 pounds)
Reactions: Anaemia, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Breast Cancer
Start date: 2010-11-10
End date: 2011-01-12
Doxorubicin Hydrochloride
Dosage: 60mgm2 cyclic
Indication: Breast Cancer
Start date: 2010-11-10
End date: 2011-01-12
Paclitaxel
Dosage: 65mgm2 cyclic
Indication: Breast Cancer
Start date: 2011-02-03
End date: 2011-04-13
Pazopanib
Dosage: 400mg per day
Administration route: Oral
Indication: Breast Cancer
Start date: 2011-02-03
End date: 2011-04-10
Other drugs received by patient: Armodafinil
Possible Cyclophosphamide side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-21
Patient:
Reactions: Off Label Use, Gastrointestinal Toxicity, Neutropenia, Infection
Drug(s) suspected as cause:
Carboplatin
Dosage: 6 courses in high risk
Indication: Retinoblastoma
Cyclophosphamide
Indication: Retinoblastoma
Doxorubicin HCL
Dosage: 4 courses in intermediate risk and 6 courses in high risk
Indication: Retinoblastoma
Etoposide
Indication: Retinoblastoma
Vincristine
Dosage: 4 courses in intermediate risk and 6 courses in high risk
Indication: Retinoblastoma
Other drugs received by patient: Neupogen
Possible Cyclophosphamide side effects in
Reported by a physician from Germany on 2012-08-20
Patient:
Reactions: Infection
Adverse event resulted in: death, life threatening event, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: unk
Indication: Multiple Myeloma
Start date: 2012-03-26
End date: 2012-07-05
Dexamethasone
Dosage: unk
Indication: Multiple Myeloma
Start date: 2012-03-26
End date: 2012-07-05
Velcade
Dosage: unk
Indication: Multiple Myeloma
Start date: 2012-03-26
End date: 2012-07-05
Other drugs received by patient: Zometa; Amoxicillin
Possible Cyclophosphamide side effects in male
Reported by a health professional (non-physician/pharmacist) from France on 2012-08-20
Patient: male
Reactions: Neutropenia, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Start date: 2012-05-21
End date: 2012-05-21
Cyclophosphamide
Start date: 2012-07-02
End date: 2012-07-02
Cyclophosphamide
Start date: 2012-07-23
End date: 2012-07-23
Cyclophosphamide
Start date: 2012-06-11
End date: 2012-06-11
Doxorubicin Hydrochloride
Start date: 2012-05-21
End date: 2012-05-21
Doxorubicin Hydrochloride
Start date: 2012-06-11
End date: 2012-06-11
Doxorubicin Hydrochloride
Start date: 2012-07-23
End date: 2012-07-23
Doxorubicin Hydrochloride
Start date: 2012-07-02
End date: 2012-07-02
Etopophos Preservative Free
Start date: 2012-06-11
End date: 2012-06-11
Etopophos Preservative Free
Start date: 2012-07-02
End date: 2012-07-02
Etopophos Preservative Free
Start date: 2012-07-23
End date: 2012-07-23
Etopophos Preservative Free
Start date: 2012-05-21
End date: 2012-05-21
Mabthera
Start date: 2012-05-21
End date: 2012-05-21
Mabthera
Start date: 2012-07-02
End date: 2012-07-02
Mabthera
Start date: 2012-06-11
End date: 2012-06-11
Mabthera
Start date: 2012-07-23
End date: 2012-07-23
Other drugs received by patient: Acetaminophen; Lovenox; Nexium; Crestor; Clopidogrel Bisulfate and Aspirin; Valacyclovir Hydrochloride; Acebutolol
Possible Cyclophosphamide side effects in male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-17
Patient: male, weighing 79.0 kg (173.8 pounds)
Reactions: Cystitis Haemorrhagic, Adenovirus Infection, Human Polyomavirus Infection, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Campath
Dosage: 30 mg/m2, 3 times per 1 cycle
Indication: Chronic Lymphocytic Leukaemia
Start date: 2008-07-15
End date: 2008-12-03
Cyclophosphamide
Dosage: 500 mg/m2, unk
Administration route: Oral
Indication: Chronic Lymphocytic Leukaemia
Start date: 2008-07-15
End date: 2008-12-03
Fludara
Dosage: 80 mg/m2, unk
Administration route: Oral
Indication: Chronic Lymphocytic Leukaemia
Start date: 2008-07-15
End date: 2008-12-03
Other drugs received by patient: Vfend; Bactrim; Valganciclovir; Folic Acid
Possible Cyclophosphamide side effects in
Reported by a health professional (non-physician/pharmacist) from Denmark on 2012-08-14
Patient:
Reactions: Transplant Failure, Cardiac Failure, Myelodysplastic Syndrome, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Carmustine
Indication: Mantle Cell Lymphoma
Cyclophosphamide
Indication: Mantle Cell Lymphoma
Cytarabine
Indication: Mantle Cell Lymphoma
Doxorubicin HCL
Indication: Mantle Cell Lymphoma
Etoposide
Indication: Mantle Cell Lymphoma
Mabthera
Indication: Mantle Cell Lymphoma
Melphalan Hydrochloride
Indication: Mantle Cell Lymphoma
Prednisolone
Indication: Mantle Cell Lymphoma
Vincristine
Indication: Mantle Cell Lymphoma
Possible Cyclophosphamide side effects in
Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-08-13
Patient:
Reactions: Pulmonary Embolism, Multiple Myeloma, Peripheral Sensory Neuropathy, Constipation, Somnolence, Death, Complications of Transplant Surgery, Peripheral Motor Neuropathy, Thrombosis in Device, Blood Alkaline Phosphatase Increased, Pancytopenia, Multiple Fractures, Rash, Renal Failure, Osteonecrosis of JAW, Embolism, Hypothyroidism, Deep Vein Thrombosis, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Multiple Myeloma
Dexamethasone
Dosage: 40 milligram
Administration route: Oral
Dexamethasone
Dosage: 20 milligram
Indication: Multiple Myeloma
Thalidomide
Dosage: or 4 weeks and increased every 4 weeks in 50-mg increments to a maximum of 200mg/day
Administration route: Oral
Indication: Multiple Myeloma
Other drugs received by patient: Melphalan Hydrochloride; Prednisolone; CLO; ZOL; Melphalan Hydrochloride; Biphosphonate; Vincristine; Doxorubicin Hydrochloride; Bortezomib
Possible Cyclophosphamide side effects in
Reported by a health professional (non-physician/pharmacist) from Canada on 2012-08-09
Patient:
Reactions: Dermatitis Allergic, Pneumonia, Angina Pectoris, Febrile Neutropenia, Cognitive Disorder, Hepatitis, Arrhythmia, Interstitial Lung Disease, Gastrointestinal Disorder, Progressive Multifocal Leukoencephalopathy, Cardiac Failure Congestive, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin Hydrochloride
Indication: Diffuse Large B-Cell Lymphoma
Prednisone TAB
Indication: Diffuse Large B-Cell Lymphoma
Radiotherapy
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Possible Cyclophosphamide side effects in
Reported by a physician from Spain on 2012-08-06
Patient:
Reactions: Skin Toxicity, Sudden Death, Hepatic Failure, Encephalitis, Cytomegalovirus Colitis, Pneumonia Pneumococcal, Neurotoxicity, Death, Multi-Organ Failure, Metastasis, Cardiotoxicity, AIDS Dementia Complex, Pseudomonas Infection, Toxicity To Various Agents, Staphylococcal Infection, Pneumonia Herpes Viral, Neutropenia, Escherichia Infection, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: given on day 1 of the 3 week cycle
Indication: Lymphoma AIDS Related
Doxorubicin HCL
Dosage: given on day 1 of the 3 week cycle
Indication: Lymphoma AIDS Related
Mabthera
Dosage: given on day 1 of every 3 week cycle (prior to chop)
Indication: Lymphoma AIDS Related
Prednisone TAB
Dosage: given for 5 days
Administration route: Oral
Indication: Lymphoma AIDS Related
Vincristine Sulfate
Dosage: given on day 1 of 3 week cycle.
Indication: Lymphoma AIDS Related
Other drugs received by patient: Hydrocortisone; Cytarabine; Methotrexate
Possible Cyclophosphamide side effects in
Reported by a physician from Denmark on 2012-08-06
Patient:
Reactions: Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Carmustine
Dosage: on day 1; beam/c
Indication: Mantle Cell Lymphoma
Cyclophosphamide
Dosage: day 1; cycle 5; chop regimen
Indication: Mantle Cell Lymphoma
Cyclophosphamide
Dosage: day 1; cycle 1; chop regimen
Cyclophosphamide
Dosage: day 2-5 in beac regimen
Cyclophosphamide
Dosage: day 1; cycle 3; chop regimen
Cytarabine
Dosage: 3 or 2 g/m2, four-3 hour infusions; cycle 4
Indication: Mantle Cell Lymphoma
Cytarabine
Dosage: 3 or 2 g/m2, four-3 hour infusions; cycle 2
Cytarabine
Dosage: day 2-5 in beam or beac regimen
Cytarabine
Dosage: 3 or 2 g/m2, four-3 hour infusions; cycle 6
Doxorubicin HCL
Dosage: on day 1; cycle 3
Indication: Mantle Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1; cycle 1
Doxorubicin HCL
Dosage: on day 1; cycle 5
Etoposide
Dosage: day 2- 5; beam/c regimen
Indication: Mantle Cell Lymphoma
Melphalan Hydrochloride
Dosage: on day 6; beam regimen
Indication: Mantle Cell Lymphoma
Prednisolone
Dosage: on day 1-5; cycle 1
Prednisolone
Dosage: on day 1-5; cycle 3
Prednisolone
Dosage: on day 1-5; cycle 5
Indication: Mantle Cell Lymphoma
Rituximab
Dosage: day 1 cycle 5
Rituximab
Dosage: day1 cycle 6, also given on day 9 for in-vivo purging
Rituximab
Dosage: day 1 from cycle 4
Indication: Mantle Cell Lymphoma
Vincristine
Dosage: on day 1 ; cycle 5
Vincristine
Dosage: on day 1; cycle 1
Indication: Mantle Cell Lymphoma
Vincristine
Dosage: on day 1; cycle 3
Possible Cyclophosphamide side effects in 76 year old
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-02
Patient: 76 year old
Reactions: Lung Disorder, Neutropenia, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin Hydrochloride
Indication: Diffuse Large B-Cell Lymphoma
Prednisone
Dosage: daily for 5 days
Indication: Diffuse Large B-Cell Lymphoma
Radiotherapy
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Other drugs received by patient: Neupogen
Possible Cyclophosphamide side effects in
Reported by a physician from United Kingdom on 2012-08-01
Patient:
Reactions: Neutropenia, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1440 mg, unk
Indication: Mantle Cell Lymphoma
Doxorubicin Hydrochloride
Dosage: 96 mg, unk
Indication: Mantle Cell Lymphoma
Prednisone
Dosage: 100 mg, unk
Indication: Mantle Cell Lymphoma
Prednisone
Dosage: 80 unk, unk
Velcade
Dosage: 3 mg, unk
Indication: Mantle Cell Lymphoma
Start date: 2011-01-27
Vincristine
Indication: Mantle Cell Lymphoma
Other drugs received by patient: Sando K / 00031402 /
Possible Cyclophosphamide side effects in
Reported by a physician from United Kingdom on 2012-07-25
Patient:
Reactions: Neutropenia, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1440 mg, unk
Indication: Mantle Cell Lymphoma
Doxorubicin Hydrochloride
Dosage: 96 mg, unk
Indication: Mantle Cell Lymphoma
Prednisone
Dosage: 80 unk, unk
Prednisone
Dosage: 100 mg, unk
Indication: Mantle Cell Lymphoma
Velcade
Dosage: 3 mg, unk
Indication: Mantle Cell Lymphoma
Start date: 2011-01-27
Vincristine
Indication: Mantle Cell Lymphoma
Other drugs received by patient: Sando K / 00031402 /
Possible Cyclophosphamide side effects in
Reported by a physician from United States on 2012-07-23
Patient:
Reactions: Drug Ineffective, B-Cell Lymphoma, Palmar-Plantar Erythrodysaesthesia Syndrome, Device Related Infection, Upper Respiratory Tract Infection, Nervous System Disorder, Adverse Event, Lymphoma, Diffuse Large B-Cell Lymphoma, Mucosal Infection, Lymphoma AIDS Related, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Lymphoma AIDS Related
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: Lymphoma AIDS Related
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphoma AIDS Related
Rituximab
Indication: Lymphoma AIDS Related
Vincristine
Dosage: not more than 2mg
Indication: Lymphoma AIDS Related
Other drugs received by patient: Antiretroviral Medications; Neupogen; Quinolone; Unknown Medication; Neupogen; Unknown Medication; Pegfilgrastim
Possible Cyclophosphamide side effects in
Reported by a physician from United Kingdom on 2012-07-19
Patient:
Reactions: Neutropenia, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1440 mg, unk
Indication: Mantle Cell Lymphoma
Doxorubicin HCL
Dosage: 96 mg, unk
Indication: Mantle Cell Lymphoma
Prednisone
Dosage: 100 mg, unk
Indication: Mantle Cell Lymphoma
Prednisone
Dosage: 80 unk, unk
Velcade
Dosage: 3 mg, unk
Indication: Mantle Cell Lymphoma
Start date: 2011-01-27
Vincristine
Indication: Mantle Cell Lymphoma
Other drugs received by patient: Sando K / 00031402 /
Possible Cyclophosphamide side effects in 39 year old female
Reported by a physician from United States on 2012-07-18
Patient: 39 year old female, weighing 88.8 kg (195.4 pounds)
Reactions: Dermatitis, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 600mgm2 cyclic
Indication: Breast Cancer
Start date: 2011-02-24
End date: 2011-05-05
Doxorubicin HCL
Dosage: 60mgm2 cyclic
Indication: Breast Cancer
Start date: 2011-02-24
End date: 2011-05-05
Paclitaxel
Dosage: 80mgm2 cyclic
Indication: Breast Cancer
Start date: 2011-05-26
End date: 2011-09-01
Pazopanib
Dosage: 400mg per day
Administration route: Oral
Indication: Breast Cancer
Start date: 2011-11-09
End date: 2012-02-27
Radiation
Indication: Breast Cancer
Start date: 2011-11-16
End date: 2011-12-21
Other drugs received by patient: Tamoxifen Citrate; Silvadene; Aquaphor; Lisinopril; Norvasc; Santyl
Possible Cyclophosphamide side effects in
Reported by a physician from Japan on 2012-07-17
Patient:
Reactions: Neuropathy Peripheral, Interstitial Lung Disease, Neutropenia, Infection
Drug(s) suspected as cause:
Cyclophosphamide
Indication: B-Cell Lymphoma
Doxorubicin HCL
Indication: B-Cell Lymphoma
Neupogen
Indication: B-Cell Lymphoma
Prednisolone
Indication: B-Cell Lymphoma
Rituxan
Dosage: 6 doses-2 days prior to each cycle of chop
Indication: B-Cell Lymphoma
Vincristine
Indication: B-Cell Lymphoma
Possible Cyclophosphamide side effects in
Reported by a physician from United Kingdom on 2012-07-17
Patient:
Reactions: Abdominal Pain, Tachycardia, Skin Toxicity, Pyrexia, Fatigue, Neuropathy Peripheral, Hepatotoxicity, Adverse Event, Dizziness, Oedema, Hallucination, Vomiting, Nausea, Gastrointestinal Toxicity, Neutropenic Sepsis, Nephropathy Toxic, Hypotension, Condition Aggravated, Adult T-Cell Lymphoma / Leukaemia, Mucosal Inflammation, Lung Disorder, Infection, Infusion Related Reaction
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1 of 21 day cycle, (cycle 1-5)
Indication: Adult T-Cell Lymphoma / Leukaemia
Cytarabine
Indication: Adult T-Cell Lymphoma / Leukaemia
Doxorubicin HCL
Dosage: on day 1 of 21 day, (cycle 1-5)
Doxorubicin HCL
Dosage: on day 1 of 21 day, (cycle 1-5)
Indication: Adult T-Cell Lymphoma / Leukaemia
Hydrocortisone
Indication: Adult T-Cell Lymphoma / Leukaemia
Methotrexate
Indication: Adult T-Cell Lymphoma / Leukaemia
Prednisolone
Dosage: on days 1-5 of 21 day cycle, (cycle 1-5)
Administration route: Oral
Indication: Adult T-Cell Lymphoma / Leukaemia
Radiotherapy
Indication: Adult T-Cell Lymphoma / Leukaemia
Vincristine
Dosage: (maximum 2 mg) on day 1 of 21 day cycle, (cycle 1-5)
Indication: Adult T-Cell Lymphoma / Leukaemia
Zenapax
Dosage: on days 7 and 14 on cycle 1 of 21 day cycle
Indication: Adult T-Cell Lymphoma / Leukaemia
Other drugs received by patient: Acyclovir; Thiabendazole; Cotrim; Itraconazole
Possible Cyclophosphamide side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-16
Patient:
Reactions: B-Cell Lymphoma, Myelodysplastic Syndrome, Neutropenia, Infection
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Chronic Lymphocytic Leukaemia
Fludarabine Phosphate
Indication: Chronic Lymphocytic Leukaemia
Mabthera
Indication: Chronic Lymphocytic Leukaemia
Possible Cyclophosphamide side effects in
Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-07-13
Patient:
Reactions: Neuropathy Peripheral, Neutropenia, Infection, Infusion Related Reaction
Drug(s) suspected as cause:
Cyclophosphamide
Indication: B-Cell Lymphoma
Doxorubicin HCL
Dosage: 6-821 day cycles; n=28
Indication: B-Cell Lymphoma
Doxorubicin HCL
Dosage: 6-821 day cycles; n=28
Obinutuzumab
Indication: B-Cell Lymphoma
Prednisone
Indication: B-Cell Lymphoma
Vincristine
Indication: B-Cell Lymphoma
Possible Cyclophosphamide side effects in
Reported by a individual with unspecified qualification from Croatia (Local Name: Hrvatska) on 2012-07-13
Patient:
Reactions: Mucosal Inflammation, Multi-Organ Failure, Tumour Lysis Syndrome, Febrile Neutropenia, Infection
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Burkitt's Lymphoma
Cytarabine
Indication: Burkitt's Lymphoma
Dexamethasone
Indication: Burkitt's Lymphoma
Doxorubicin Hydrochloride
Indication: Burkitt's Lymphoma
Etoposide
Indication: Burkitt's Lymphoma
Ifosfamide
Indication: Burkitt's Lymphoma
Mabthera
Indication: Burkitt's Lymphoma
Methotrexate
Indication: Burkitt's Lymphoma
Methylprednisolone
Indication: Prophylaxis
Prednisone
Indication: Burkitt's Lymphoma
Vincristine
Indication: Burkitt's Lymphoma
Possible Cyclophosphamide side effects in
Reported by a physician from United Kingdom on 2012-07-10
Patient:
Reactions: Abdominal Pain, Skin Toxicity, Tachycardia, Pyrexia, Fatigue, Neuropathy Peripheral, Hepatotoxicity, Adverse Event, Oedema, Dizziness, Hallucination, Vomiting, Gastrointestinal Toxicity, Nausea, Neutropenic Sepsis, Nephropathy Toxic, Hypotension, Adult T-Cell Lymphoma / Leukaemia, Condition Aggravated, Mucosal Inflammation, Lung Disorder, Infection, Infusion Related Reaction
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1 of 21 day cycle, (cycle 1-5)
Indication: Adult T-Cell Lymphoma / Leukaemia
Cytarabine
Indication: Adult T-Cell Lymphoma / Leukaemia
Doxorubicin HCL
Dosage: on day 1 of 21 day, (cycle 1-5)
Indication: Adult T-Cell Lymphoma / Leukaemia
Hydrocortisone
Indication: Adult T-Cell Lymphoma / Leukaemia
Methotrexate
Indication: Adult T-Cell Lymphoma / Leukaemia
Prednisolone
Dosage: on days 1-5 of 21 day cycle, (cycle 1-5)
Administration route: Oral
Indication: Adult T-Cell Lymphoma / Leukaemia
Radiotherapy
Indication: Adult T-Cell Lymphoma / Leukaemia
Vincristine
Dosage: (maximum 2 mg) on day 1 of 21 day cycle, (cycle 1-5)
Indication: Adult T-Cell Lymphoma / Leukaemia
Zenapax
Dosage: on days 7 and 14 on cycle 1 of 21 day cycle
Indication: Adult T-Cell Lymphoma / Leukaemia
Other drugs received by patient: Cotrim; Itraconazole; Thiabendazole; Acyclovir
Possible Cyclophosphamide side effects in
Reported by a physician from United States on 2012-07-05
Patient:
Reactions: Fatigue, Central Nervous System Haemorrhage, Erythema Multiforme, Dyspnoea, Stomatitis, Vomiting, Gastrointestinal Toxicity, Nausea, Condition Aggravated, Rash, Haematotoxicity, Pulmonary Haemorrhage, Tumour Lysis Syndrome, Diarrhoea, Respiratory Failure, Neurological Symptom, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: for 5 days in cycle 1
Indication: Burkitt's Lymphoma
Cyclophosphamide
Dosage: days 1-5 during cycle 3,5 and 7
Cyclophosphamide
Dosage: for 5 days in cycle 1
Indication: Burkitt's Leukaemia
Cyclophosphamide
Dosage: days 1-5 during cycle 3,5 and 7
Cytarabine
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Cytarabine
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Dexamethasone Sodium Phosphate
Dosage: on days 1-5 of cycle 2,4 and 6
Dexamethasone Sodium Phosphate
Dosage: on days 1-5 of cycle 2,4 and 6
Dexamethasone Sodium Phosphate
Dosage: on days 1-5 of cycle 3,5 and 7
Indication: Burkitt's Leukaemia
Dexamethasone Sodium Phosphate
Dosage: on days 1-5 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Doxorubicin HCL
Dosage: on days 4 and 5 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Doxorubicin HCL
Dosage: on days 4 and 5 of cycle 3,5 and 7
Indication: Burkitt's Leukaemia
Etoposide
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Etoposide
Dosage: on days 4 and 5 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Ifosfamide
Dosage: on days 1-5 in cycle 2,4 and 6
Indication: Burkitt's Lymphoma
Ifosfamide
Dosage: on days 1-5 in cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Methotrexate
Dosage: on day 1 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Methotrexate
Dosage: on day 1 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Methotrexate
Dosage: on day 1 of cycle 3,5 and 7
Methotrexate
Dosage: on day 1 of cycle 2,4 and 6
Prednisone
Dosage: for 7 days in cycle 1
Indication: Burkitt's Lymphoma
Prednisone
Dosage: for 7 days in cycle 1
Indication: Burkitt's Leukaemia
Rituximab
Dosage: on day 8 from cycle 3 to 7
Rituximab
Dosage: on day 8 from cycle 3 to 7
Rituximab
Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
Indication: Burkitt's Leukaemia
Rituximab
Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
Indication: Burkitt's Lymphoma
Vincristine
Dosage: on day 1 of cycle 3,5 and 7
Indication: Burkitt's Lymphoma
Vincristine
Dosage: on day 1 of cycle 2,4 and 6
Vincristine
Dosage: on day 1 of cycle 3,5 and 7
Vincristine
Dosage: on day 1 of cycle 2,4 and 6
Indication: Burkitt's Leukaemia
Other drugs received by patient: Filgrastim; Unknown Medication; Leucovorin Calcium
Possible Cyclophosphamide side effects in
Reported by a health professional (non-physician/pharmacist) from Japan on 2012-07-05
Patient:
Reactions: Neuropathy Peripheral, Interstitial Lung Disease, Neutropenia, Infection
Drug(s) suspected as cause:
Cyclophosphamide
Indication: B-Cell Lymphoma
Doxorubicin HCL
Indication: B-Cell Lymphoma
Neupogen
Indication: B-Cell Lymphoma
Prednisolone
Indication: B-Cell Lymphoma
Rituximab
Dosage: 6 doses-2 days prior to each cycle of chop
Indication: B-Cell Lymphoma
Vincristine
Indication: B-Cell Lymphoma
Page 1 Next >>
|
